{"url_path":"/sec/erna/8-k/2026-06-26/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/748592/0001493152-26-030306-index.html","accession_number":"0001493152-26-030306","cik":"0000748592","ticker":"ERNA","issuer_name":"Ernexa Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/748592/0001493152-26-030306-index.html","primary_entity_key":"0000748592","primary_entity_name":"Ernexa Therapeutics Inc."},"word_count":207,"has_tables":true,"body_markdown":"**Item 5.02**\n**Departure\nof Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn\nJune 22, 2026, Sandra Gurrola, Senior Vice President of Finance of Ernexa Therapeutics Inc., a Delaware corporation (the “Company”),\ndelivered her notice of resignation, with such resignation becoming effective July 3, 2026. Ms. Gurrola’s resignation was not a\nresult of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.\n\n \n\nFollowing\nthe effective date of her resignation, Ms. Gurrola has agreed to provide transition assistance to the Company on a part-time basis for\nup to 10 hours per week through the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.\nThe Company has not yet determined the compensation, if any, payable to Ms. Gurrola for such transition services. If the Company enters\ninto or approves a material compensatory arrangement with Ms. Gurrola in connection with her resignation or transition services, the\nCompany will disclose such arrangement in accordance with applicable SEC rules.\n\n \n\nThe\nCompany has initiated a search to identify a successor. Until a successor is appointed, the Company expects to use additional outside\nsupport to assist with finance, accounting, and reporting matters."}